Jian Yu

Professor of Medicine

Image of Jian Yu
Is this your profile? Click to edit

Overview

My research explores mechanistic coupling of intestinal stem cell injury with regeneration, focusing on cancer driver-dependent regulation of cell death, stress adaptation, and immunologic outcomes. Our long-term goal is to identify novel targets and agents for colon cancer prevention and treatment through stem cell and niche normalization and epithelial barrier longevity. I have been active in teaching and mentoring students, postdoctoral fellows, and junior faculty.

Secondary appointment: Professor of Cancer Biology

Publications
-My NCBI
https://www.ncbi.nlm.nih.gov/myncbi/jian.yu.1/bibliography/public/
-Google Scholar
https://scholar.google.com/citations?user=yXODGQYAAAAJ&hl=en&authuser=1

Awards

  • Johns Hopkins University School of Medicine: Michael A. Shanoff Research Excellence Award, 2001
  • The Flight Attendant Medical Research Institute: Young Clinical Scientist Award, 2003
  • The Hillman Foundation: The Hillman Fellow of Innovative Cancer Research, 2004
  • The Alliance for Cancer Gene Therapy: Young Investigator Award, 2005
  • University of Pittsburgh Cancer Institute: Junior Scholar Award, 2008
  • American Cancer Society: Research Scholar Award, 2010
  • University of Pittsburgh: Innovator Award, 2011

Education and Training

  • Sichuan University, Chengdu, China — BS — 07/1991 — Chemistry
  • Johns Hopkins University, Baltimore, USA — PhD — 05/2001 — Human Genetics and Molecular Biology
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins , Baltimore, USA — Fellowship, postdoctoral — 06/2002 — Oncology

Research Funding

  • LR-IL-22 for Mitigation and Management of Radiation Injuries
    NIH/NIAID · U01 AI172885 · Dec 1, 2022 – Nov 30, 2027 · Role: Co-Investigator
  • STING-dependent Intestinal Regeneration upon Radiation Injury
    NIH/NCI · R01CA260900 · Feb 9, 2022 – Jan 31, 2027 · Role: Principal Investigator
  • STING-dependent Intestinal Regeneration upon Radiation Injury
    NIH · R01CA260900 · Feb 7, 2022 – Aug 31, 2027 · Role: Principal Investigator
  • BET degraders for improving colorectal cancer therapy
    NIH/NCI · R01CA248112 · Apr 1, 2021 – Mar 31, 2026 · Role: Co-Investigator
  • Targeting defective necroptosis in colorectal cancer
    NIH · R01CA247231 · Dec 1, 2019 – Mar 31, 2025 · Role: Co-Principal Investigator
  • Targeting defective necroptosis in colorectal cancer
    NIH/NCI · R01CA247231 · Dec 1, 2019 – Nov 30, 2024 · Role: Co-Principle Investigator, MPI
  • Translation addiction and targeting in colon cancer
    NIH/NCI · R01CA215481 · Jan 1, 2018 – Mar 31, 2023 · Role: Principle Investigator
  • Translation addiction and targeting in colon cancer
    NIH · R01CA215481 · Jan 1, 2018 – Mar 31, 2023 · Role: Principal Investigator
  • Intestinal Stem Cell Survival and Renewal Coordinately Regulated by PUMA and p21
    NIH · U01DK085570 · Sep 30, 2009 – Aug 31, 2015 · Role: Principal Investigator
  • Role of PUMA in EGFR targeted therapy in HNSCC
    NIH · R01CA129829 · Aug 1, 2008 – May 31, 2014 · Role: Principal Investigator

Research Keywords

  • cell death
  • stress adaptation
  • intestinal stem cell
  • colon cancer
  • inflammation

Publications

  • Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer. Mol Biomed. 2022 Mar 21; 3(1):10.. View in PubMed
  • tRF3008A suppresses the progression and metastasis of colorectal cancer by destabilizing FOXK1 in an AGO-dependent manner. J Exp Clin Cancer Res. 2022 Jan 22; 41(1):32.. View in PubMed
  • Role of Receptor Interacting Protein (RIP) kinases in cancer. Genes Dis. 2022 Nov; 9(6):1579-1593.. View in PubMed
  • BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade. Oncogene. 2021 12; 40(48):6566-6578.. View in PubMed
  • Interferon b drives intestinal regeneration after radiation. Sci Adv. 2021 Oct 08; 7(41):eabi5253.. View in PubMed
  • M6A “Writer” Gene METTL14: A Favorable Prognostic Biomarker and Correlated With Immune Infiltrates in Rectal Cancer. Front Oncol. 2021; 11:615296.. View in PubMed
  • Non-steroidal anti-inflammatory drugs induce immunogenic cell death in suppressing colorectal tumorigenesis. Oncogene. 2021 03; 40(11):2035-2050.. View in PubMed
  • HDAC2 inhibits EMT-mediated cancer metastasis by downregulating the long noncoding RNA H19 in colorectal cancer. J Exp Clin Cancer Res. 2020 Dec 02; 39(1):270.. View in PubMed
  • eIF4E S209 phosphorylation licenses myc- and stress-driven oncogenesis. Elife. 2020 11 02; 9.. View in PubMed
  • Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. Biochim Biophys Acta Rev Cancer. 2020 12; 1874(2):188447.. View in PubMed